The MyoThrombus study
Research type
Research Study
Full title
Exploration of cardiovascular thrombus activity post myocardial infarction by using 18F-GP1 MR/PET
IRAS ID
255883
Contact name
Marc Dweck
Contact email
Sponsor organisation
Univeristy of Edinburgh
Clinicaltrials.gov Identifier
RG/16/10/32375, BHF Programme grant
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
We aim to examine whether 18F-GP1 (radiotracer that binds in active clot components) can be used to explore the thrombosis process (clotting) which is a process that affects various common conditions including heart attacks. In particular, clots inside the heart chambers (i.e. left ventricle) appear to be very common after a major heart attack but we haven’t investigated their timeline and consequences. These clots are linked with a risk of stroke if left untreated.
18F-GP1 has been already been used safely in humans demonstrating acceptable radiation doses. In preliminary data from pilot studies, including patients with clots in various organs (leg veins, lungs, brains), 18F-GP1 proved to be a really good tracer for imaging active clots.
In this study we are going to explore the clotting activity inside the heart and brain following myocardial infarction and to establish the time point of maximal clotting activity in these areas. We also aim to look at clots inside the heart arteries (intracoronary) and the heart muscle (intramyocardial bleeding).
We are aiming to administer the tracer (18F-GP1) in 100 patients (male and female) over the age of 40, following myocardial infarction. This will be followed by a dedicated scan of the heart and brain (PET/MR of heart and brain). Patients who have positive scans (possible clot in the heart or brain) will return for two repeat PET/MR scans after 3 and 6 months if the clinical team decides not to administer blood thinners or 6 and 9 months if the clinical team decides to treat with blood thinners for 6 months.
REC name
South East Scotland REC 02
REC reference
20/SS/0083
Date of REC Opinion
3 Sep 2020
REC opinion
Further Information Favourable Opinion